Global Acute Ischemic Stroke Drugs Pipeline Market Research 2022: Comprehensive Information on 35+ Companies and 35+ Drugs in Pipeline –

DUBLIN–(BUSINESS WIRE)–“Global Acute Ischemic Stroke – Pipeline Insight, 2022” clinical trials added to from offer.

This “Acute Ischemic Stroke – Pipeline Insight, 2022” report provides comprehensive insights on 35+ companies and 35+ drugs under development in the acute ischemic stroke pipeline landscape.

It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

The report presents comprehensive information on the current scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided, which includes the disease overview and Acute Ischemic Stroke treatment guidelines.

The assessment part of the report includes an in-depth Acute Ischemic Stroke business assessment and clinical evaluation of the pipeline products under development. In the report, a detailed description of the drug is given including the mechanism of action of the drug, clinical studies, NDA approvals (if any) and product development activities including technology, stroke collaborations acute ischemic diseases, licensing, mergers and acquisitions, financing, designations, and other product-related details.

Emerging Acute Ischemic Stroke Drug Chapters

This segment of the Acute Ischemic Stroke report contains its detailed analysis of various drugs at different stages of clinical development including Phase II, I, Preclinical and Discovery. It also helps to understand details of clinical trials, expressive pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Emerging drugs for acute ischemic stroke

Nelonemdaz: GNT

Nelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin scavenger that reduces NMDA receptor-mediated excitotoxicity and oxidative stress, two major pathways of brain cell death leading to disability and death after stroke. Nelonemdaz has previously shown better efficacy and a longer therapeutic time window than subtype-nonselective NMDA antagonists or antioxidants alone in 5 animal models of stroke. Its safety and tolerability in humans has been established in two previous Phase I studies in 165 healthy young and elderly volunteers in the United States and China.

Tenecteplase: Genentech

Tenecteplase (TNKase, TNK-tPA or TNK) is a thrombolytic agent derived from tissue plasminogen activator (tPA), which binds fibrin and converts plasminogen to plasmin. It is a 527 amino acid glycoprotein developed by replacing three amino acids at the T, N and K positions of the tPA glycoprotein structure under genetic recombination technology. After replacing threonine 103 with asparagine, asparagine 117 with glutamine and a tetra-alanine at amino acids 296-299, TNK is about eight times more potent in dissolving clots, 80 times more resistant to plasminogen activator inhibitor-1 and 14 times higher. specificity of fibrin, and with a longer half-life (20 min). Therefore, TNK is administered as a single intravenous bolus. Tenecteplase has a well characterized mechanism of action with significant practical advantages in administration and superior clinical efficacy for patients with large vessel occlusion. It is currently being evaluated in patients with acute ischemic stroke (AIS) eligible for imaging.

SP-8203: Shin Poong

SP-8203, under development, is a new neuroprotective compound for acute ischemic stroke. It is a quinazoline-2, 4-dione derivative with multiple potent neuroprotective mechanisms of action, including anti-inflammatory activities. Patent applications have been filed in 52 countries and granted in 44 countries. SP-8203 has proven to be a first-in-class candidate that has multiple neuroprotective effects across a variety of animal models of stroke.

In particular, because it extends the therapeutic window when combined with tPA, a greater number of patients would have the benefit of reducing cerebral infarction and edema as well as bleeding and mortality. In fact, a few years after the start of the project, SP-8203 won the top 10 future pharmaceutical special projects managed by the Ministry of Health and Welfare, as it was highly appraised for its distinctiveness. Currently, the drug is in phase II clinical trial evaluation for the treatment of acute ischemic stroke.


NoNO-SC is an analogue of nerinetide for injection by subcutaneous route for the treatment of all strokes. Auto-injector (i.e. “stroke pen”) compatibility allows administration by any caregiver at home, en route to hospital or upon arrival at the ward. emergency room. Currently, the drug is in the preclinical stage of clinical trial evaluation for the treatment of acute ischemic stroke.

Acute ischemic stroke: therapeutic assessment

This segment of the report provides information about the different Acute Ischemic Stroke Drugs separated based on the following parameters which define the scope of the report such as:

Main players in acute ischemic stroke

Approx. Over 35 key companies developing therapies for acute ischemic stroke. Among the companies whose acute ischemic stroke drug candidates are at the most advanced stage, ie in phase III, we can cite GNT Pharma.


This report covers about 35+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Intermediate products (Phase II)

  • Product at an early stage (Phase I)

  • Candidates in the preclinical and discovery phase

  • Abandoned and Inactive Candidates

  • Route of administration

Products have been categorized under various ROAs such as

  • intra-articular

  • intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

  • Molecule type

The products have been categorized under different types of molecules such as

  • Oligonucleotide

  • peptide

  • small molecule

  • type of product

Acute Ischemic Stroke Report Overview

  • Acute Ischemic Stroke Pipeline Analysis

  • Therapeutic assessment

  • Unmet needs

  • Impact of drugs

Acute Ischemic Stroke Report Assessment

  • Pipeline Product Profiles

  • Therapeutic assessment

  • Pipeline assessment

  • Evaluation of inactive drugs

  • Unmet needs

Key players

  • Genentech

  • Supergene

  • Tasly Pharmaceutical

  • Pharmazz

  • GNT Pharma

  • No no

  • Angde Biotech Pharmaceuticals

  • NuvOx Pharma

  • Helios

  • Acticor Biotech

  • biogenic

  • ZZ Biotech

  • Revalesio Corporation

  • Shionogi & Co., Ltd.

  • AbbVie

  • Pharmacy Group

  • Bristol Myers Squibb

  • rock

  • Clinicuvel Pharmaceuticals

  • TrueBinding

  • Shin Poong Pharmaceutical

  • Therapeutic Lumosa

  • NC Medical Research

  • JCR Pharmaceuticals

  • aptaTargets

  • PT. Prodia Stem Cell Indonesia

Key products

  • Tenecteplase

  • Recombinant Staphylokinase

  • Recombinant prourokinase

  • Sovateltide

  • Nelonemdaz

  • Nerinetide

  • Replace

  • DDFPe

  • Invimestrocel

  • ACT-017

  • TMS-007

  • 3K3A-APC

  • RNS60

  • S-005151

  • Elezanumab

  • Conestat Alfa

  • BMS-986177

  • Balovaptan

  • Scenesse (Afamelanotide)

  • TB006

  • SP-8203

  • LT 3001

  • CNS 01

  • JTR-161

  • ApTOLL

  • Mesenchymal stem cells from the umbilical cord

For more information about this clinical trial report, visit

Comments are closed.